Mont-Saint-Guibert (Belgium), November 27, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
Contact:
Nyxoah
John Landry, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.71 |
Daily Change: | -0.37 -6.09 |
Daily Volume: | 93,114 |
Market Cap: | US$213.730M |
March 26, 2025 March 13, 2025 February 19, 2025 November 06, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load